- Home
- RLYB vs SABS Comparison
RLYB vs SABS Comparison
Compare RLYB & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLYB
- SABS
- Stock Information
- Founded
- RLYB 2018
- SABS 2014
- Country
- RLYB United States
- SABS United States
- Employees
- RLYB N/A
- SABS N/A
- Industry
- RLYB Biotechnology: Pharmaceutical Preparations
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- RLYB Health Care
- SABS Health Care
- Exchange
- RLYB Nasdaq
- SABS Nasdaq
- Market Cap
- RLYB 14.4M
- SABS 15.8M
- IPO Year
- RLYB 2021
- SABS N/A
- Fundamental
- Price
- RLYB $0.38
- SABS $1.87
- Analyst Decision
- RLYB Hold
- SABS Strong Buy
- Analyst Count
- RLYB 3
- SABS 6
- Target Price
- RLYB $15.00
- SABS $11.17
- AVG Volume (30 Days)
- RLYB 163.1K
- SABS 75.7K
- Earning Date
- RLYB 05-08-2025
- SABS 06-10-2025
- Dividend Yield
- RLYB N/A
- SABS N/A
- EPS Growth
- RLYB N/A
- SABS N/A
- EPS
- RLYB N/A
- SABS N/A
- Revenue
- RLYB $848,000.00
- SABS $377,835.00
- Revenue This Year
- RLYB N/A
- SABS N/A
- Revenue Next Year
- RLYB N/A
- SABS $50.00
- P/E Ratio
- RLYB N/A
- SABS N/A
- Revenue Growth
- RLYB N/A
- SABS N/A
- 52 Week Low
- RLYB $0.22
- SABS $1.00
- 52 Week High
- RLYB $1.73
- SABS $5.01
- Technical
- Relative Strength Index (RSI)
- RLYB 59.08
- SABS 55.57
- Support Level
- RLYB $0.27
- SABS $1.73
- Resistance Level
- RLYB $0.37
- SABS $2.00
- Average True Range (ATR)
- RLYB 0.05
- SABS 0.17
- MACD
- RLYB 0.01
- SABS -0.01
- Stochastic Oscillator
- RLYB 81.54
- SABS 47.75
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.